Directorio

We are doing this study to understand how hand transplantation can help you with your daily activities compared to before the transplant.

We are doing this study to better understand how HIV affects the body.

The purpose of this study is to find out if combining a bispecific antibody with a drug called selinexor (XPOVIO) is a safe and effective option for multiple myeloma patients whose disease has returned after treatment or did not adequately respond to treatment.

We are doing this study to find out if an experimental drug called pacritinib (the study drug) is a safe and effective treatment for people with T-cell lymphoproliferative cancers. We want to know how well it works for patients diagnosed with peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL).

We are doing this study to collect blood samples that may be used for the following:

• To make sure equipment and assays are working properly
• Staff training
• Researching assay development (an assay is a laboratory test)

This study uses a system called Hemanext ONE that keeps red blood cells in low oxygen. The study lasts about fourteen months. During the study, you will receive two kinds of blood transfusions. One kind uses low oxygen blood, and the other uses regular blood. The order is chosen by chance. Each type of transfusion lasts six months, with a two month break in between. At each visit, doctors will check your vital signs, do blood tests, and ask how you are feeling. There is also an optional visit one day after a transfusion for extra blood tests.